Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 7/2010

01-07-2010 | Healthcare Policy and Outcomes

Surgical Oncology Trials and Surgeons in the Real World!

Authors: Waddah B. Al-Refaie, MD, FACS, Peter W. P. T. Pisters, MD, FACS, David A. Rothenberger, MD, FACS

Published in: Annals of Surgical Oncology | Issue 7/2010

Login to get access

Excerpt

Randomized clinical trials (RCTs) are reputed to be critical to the everyday practice of surgery by providing high-quality evidence to guide, inform, and establish the standards of treatment for persons with cancer.1,2 RCTs are designed to minimize bias and equalize potential confounding effects of measured and unmeasured variables. To this date, RCTs remain the gold standard to assess the efficacy of alternative interventions, as enormous resources and time are expended to conceive, conduct, monitor, and complete cancer trials. The ultimate goal of this effort is to improve survival and functional outcomes of patients with cancer, but achieving this goal requires rapid adoption and wide-scale implementation of trial results into standard clinical practice. …
Literature
1.
2.
3.
Brooks AD, Karpoff HM, Sulimanoff I, Coit D, Brennan MF, Jaques DP. The search for level I evidence in solid-tumor oncology. Ann Surg Oncol. 2001;8:638–43.CrossRefPubMed
4.
Elting LS, Cooksley C, Bekele BN, Frumovitz M, Avritscher EB, Sun C, et al. Generalizability of cancer clinical trial results: prognostic differences between participants and nonparticipants. Cancer. 2006;106:2452–8.CrossRefPubMed
5.
6.
Dilts DM, Sandler AB. Invisible barriers to clinical trials: the impact of structural, infrastructural, and procedural barriers to opening oncology clinical trials. J Clin Oncol. 2006;24:4545–52.CrossRefPubMed
7.
Swanson GM, Bailar JC, 3rd. Selection and description of cancer clinical trials participants—science or happenstance? Cancer. 2002;95:950–9.CrossRefPubMed
8.
Lund MJ, Eliason MT, Haight AE, Ward KC, Young JL, Pentz RD. Racial/ethnic diversity in children’s oncology clinical trials: ten years later. Cancer. 2009;115:3808–16.CrossRefPubMed
9.
Stewart JH, Bertoni AG, Staten JL, Levine EA, Gross CP. Participation in surgical oncology clinical trials: gender-, race/ethnicity-, and age-based disparities. Ann Surg Oncol. 2007;14:3328–34.CrossRefPubMed
10.
Gross CP, Filardo G, Mayne ST, Krumholz HM. The impact of socioeconomic status and race on trial participation for older women with breast cancer. Cancer. 2005;103:483–91.CrossRefPubMed
11.
Hutchins LF, Unger JM, Crowley JJ, Coltman CA, Jr, Albain KS. Underrepresentation of patients 65 years of age or older in cancer-treatment trials. N Engl J Med. 1999;341:2061–7.CrossRefPubMed
12.
Murthy VH, Krumholz HM, Gross CP. Participation in cancer clinical trials: race-, sex-, and age-based disparities. JAMA. 2004;291:2720–6.CrossRefPubMed
13.
Newman LA, Hurd T, Leitch M, Kuerer HM, Diehl K, Lucci A, et al. A report on accrual rates for elderly and minority-ethnicity cancer patients to clinical trials of the American College of Surgeons Oncology Group. J Am Coll Surg. 2004;199:644–51.CrossRefPubMed
14.
Al-Refaie WB, Habermann EB, Dudeja V, Vickers SM, Tuttle TM, Jensen EH, et al. Extremity soft tissue sarcoma care in the elderly: insights into the generalizability of NCI trials. Ann Surg Oncol. 2010 [Epub ahead of print].
15.
Al-Refaie WB, Parsons HM, Henderson WG, Jensen EH, Tuttle TM, Vickers SM, et al. Major cancer surgery in the elderly: results from the American College of Surgeons National Surgical Quality Improvement Program. Ann Surg. 2010;251:311–8.CrossRefPubMed
16.
Lamont EB, Landrum MB, Keating NL, Archer L, Lan L, Strauss GM, et al. Differences in clinical trial patient attributes and outcomes according to enrollment setting. J Clin Oncol. 2010;28:215–21.CrossRefPubMed
Metadata
Title
Surgical Oncology Trials and Surgeons in the Real World!
Authors
Waddah B. Al-Refaie, MD, FACS
Peter W. P. T. Pisters, MD, FACS
David A. Rothenberger, MD, FACS
Publication date
01-07-2010
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 7/2010
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1069-1

Other articles of this Issue 7/2010

Annals of Surgical Oncology 7/2010 Go to the issue

Breast Oncology

Invasive Lobular vs. Ductal Breast Cancer: A Stage-Matched Comparison of Outcomes

Healthcare Policy and Outcomes

Consensus Statement on the Adoption of the COPE Guidelines

Healthcare Policy and Outcomes

Extremity Soft Tissue Sarcoma Care in the Elderly: Insights into the Generalizability of NCI Cancer Trials

Pancreatic Tumors

A Simple Risk Score to Predict In-Hospital Mortality After Pancreatic Resection for Cancer

Thoracic Oncology

An Evaluation of the Number of Lymph Nodes Examined and Survival for Node-Negative Esophageal Carcinoma: Data from China

Gastrointestinal Oncology

Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation